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ABSTRACT 
 
 
  
 The purpose of this IQP was to explore the technology of stem cells, focusing on ethics 
and legalities. Our findings indicate that although most human embryonic stem (ES) cell 
applications remain as future applications, some types of adult stem cells (ASCs) have already 
been used to save lives.  None of the five major world religions is against working with ASCs, 
especially when used to save human lives, however ES cell research still has not received much 
approval from many conservative Christian groups.  Restrictive U.S. legislations on ES cell 
research by conservative governments such as the current US administration has hindered ES 
cell progress. 
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PROJECT OBJECTIVES 
 
 
 The goals of this IQP were to explore the topic of stem cells and their applications, and to 
discuss the effect of this controversial technology on society.  Key debate points were discussed 
from the last few decades, to the present and future.  The specific aim of chapter-1 was to 
describe and contrast the various types of stem cells, to clarify the key point that not all stem 
cells are alike. The objective of chapter-2 was to investigate examples where stem cells have 
successfully been implemented and studied, paying particular attention to distinguish hype from 
reality. The purpose of chapter-3 was to explore the ethics surrounding stem cell research, 
especially the view of the five major world religions. The purpose of chapter-4 was to examine 
the laws governing stem cell use in the United States and other countries.  Finally, the authors of 
this project provide their own conclusions about this controversial topic.   
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Chapter-1:  Stem Cell Types and Sources 
 
 Stem cells are “immortal” cells in the body that can not only replicate themselves, they 
can also change (differentiate) into other cell types.  Due to this differentiation potential, these 
cells are thought to have medical applications in regenerative medicine, a promising new field of 
21st century medicine.  But controversies arise regarding where these stem cells are obtained, 
opening up ethical and legal concerns.  Not all stems cells are equal, and not all stem cells 
require the destruction of an embryo to obtain them.  The purpose of this chapter is to shed light 
on what stem cells are, and where we get them. 
 
Stem Cell History 
 Scientists have been interested in cell biology since the invention of the microscope in the 
1800’s, a time when the discovery that cells generate other cells was made.  However, in the 
early 1900’s, cells were discovered that not only reproduce themselves, they also change into 
other cell types, in this case a type of cell from bone marrow could generate other blood cells 
(Stem Cell Research, 2007).  Research focused on whether such cells could be used in medicine 
to regenerate blood.  In 1968, the first bone marrow transplant, containing hematopoietic stem 
cells (HSCs), was performed to treat two siblings with severe combined immunodeficiency 
disease, and since the 1970’s bone marrow transplants have been used for treatment of thousands 
of patients with immunodeficiencies and leukemias (Deem, 2004).  
 Ten years later, the first in vitro stem cell line was developed from mice. In 1988 
embryonic stem (ES) cell lines were derived from a hamster and about 7 years after that 
discovery, ES cell lines were created from a primate. In 1997 two different events happened: 
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Dolly a lamb was the first mammal cloned from stem cells, and the origin of leukemia was 
determined to be due to the replication of abnormal hematopoietic stem cells, indicating proof 
that cancer can result from abnormal stem cells.  But in 1998, the entire stem cell field achieved 
much greater public awareness when James Thomson (University of Wisconsin – Madison) 
isolated cells from the inner cell mass of an early human blastocyst embryo, and developed the 
first human ES cell lines. In the same year, John Geahart (Johns Hopkins University) derived 
human embryonic germ cells (EGCs) from fetal gonadal tissue (primordial germ cells). In 1999 
and 2000, it was discovered that different cell types can be produced by manipulating adult 
mouse tissues; nerve cells or liver cells could be produced from adult bone marrow stem cells 
(Stem Cell Research, 2007).  Soon after, the journal Science claimed that advances in stem cell 
research was the “breakthrough of the year”.   
 The stem cell field has continued to expand and attract the attention of scientists, as well 
as but also policy-makers, business interests and ethicists.   All these discoveries were exciting 
for the area of stem cell research, giving scientists the hope of obtaining greater control over 
stem cell proliferation and differentiation for medical purposes. Various laws and procedures 
regarding stem cell harvesting, development and use have been created because of national 
debates among the public, religious groups, scientists, and government officials. The main goal 
of such policies is to safeguard people from the unethical use of stem cells, while still supporting 
new discoveries.  But before attempting to understand these ethical and legal problems, it is 
necessary to understand the basic science of stem cells, including sources and types of stem cells. 
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Types and Sources 
 Stem cells have two important characteristics that distinguish them from other cell types. 
The first is the ability to renew themselves for long periods through cell division, and the second 
is their ability to differentiate into endodermal, mesodermal, or ectodermal lineages under certain 
physiological or experimental conditions. Therefore, during every cell division in vitro, one stem 
cell produces one daughter stem cell (that remains undifferentiated) and one differentiated cell 
whose properties are more specialized than the parent cell (Stem Cell Basics, 2008).  Some 
scientists have questioned this basic definition of stem cell, preferring to think of “stemness” as a 
transition state between regeneration and differentiation that changes depending on need and 
location.  
 Stem cells can broadly be divided into two types, embryonic stem (ES) cells and adult 
stem cells (ASCs), each with particular functions and characteristics that will be explained later 
in this chapter.  Stem cells can be obtained from many different sources, but not all of them are 
equal in their potentials.  Some stem cells are said to be pluripotent, meaning that they have the 
ability to develop into many different cell types of the body, some are multipotent and able to 
develop into a few other cell types, while others are mostly unipotent and somewhat restricted in 
which cell types they can become. 
 
Embryonic Stem Cells 
 Embryonic stem cells (ES) are pluripotent cells derived from embryos generated by in 
vitro fertilization (IVF).  If IVF is successful, the sperm head enters the egg, leaving the tail 
behind. Later, the fertilized cell divides by binary fusion. About 5 days after fertilization, a 
multicellular ball of cells called a blastocyst is formed (Figure-1). Typically, a blastocyst is a 
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hollow ball made of two cell types, an outer layer called the trophoblast, which eventually forms 
the placenta, and an inner cluster of cells known as the inner cell mass which becomes the  
embryo. The inner cell mass consists of ES cells, which can be picked up with a pipette and 
transferred to a Petri dish. The resulting colonies can be further propagated by transferring cells 
to new Petri dishes. Under particular culture conditions these cells start self-renewing, or 
dividing, and the cell mass starts growing (Human Embryonic Stem Cells, 2007) .  
 
 
 
 
Figure-1:  Diagram of a Human Blastocyst.  The embryo at this 
stage is composed of the trophoblast or outer layer of cells, and the 
inner cell mass from which ES cells are obtained. 
http://www.mydr.com.au/content/images/categories/Pregnancy/blast
ocyst.gif  
 
 
 
 The addition of specific growth factors or signaling molecules to ES cells can coax them 
to differentiate into a certain cell type, such as pancreatic cells, muscle cells, or nerve cells. The 
main goal of cell replacement therapy is to use this kind of cell for transplantation to replace old 
or diseased tissue and to renew function.  
 Since ES cells have such a large variety of types of cells they can become, they are said 
to be pluripotent. Moreover, they have an ability to divide, or self-renew indefinitely while 
retaining their pluripotent, undifferentiated state. For example, small numbers of ES cells can be 
placed in a Petri dish to divide, and the cells from one Petri dish can be used to seed many other 
plates. In this case, an indefinite number of pluripotent cells can be produced (Human Embryonic 
Stem Cells, 2007).  
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SCNT 
 When transplanting ES cells obtained from an IVF embryo, the genetic component of the 
ES cells in the dish will be different from the genetic background of the patient, because the 
patient did not provide the IVF embryo.  Hence, the tissues and organs grown from these cells 
will have a different genetic background from the patient, which can cause immunorejection of 
the transplanted tissues. One solution that might help in eliminating this rejection is the somatic 
cell nuclear transfer (SCNT) technique (Figure-2). During SCNT, the nucleus of the egg with its 
genetic material is removed.  Later, a biopsy from the patient is taken (with mice this is usually a 
skin fibroblast cell), and the nucleus from one of these cells is transferred into the enucleated 
egg.  Following activation, the egg divides to the blastocyst stage from which genetically 
identical ES cells can be obtained whose genetic content is identical to the patient.  In this 
manner, patient-specific stem cells could be derived and used to produce cells and tissues for 
transplantation that will not be rejected (Soon-Chye, 2001).   This SCNT procedure has not yet 
been achieved in humans, but has worked in mice. 
 
Figure-2:  Diagram for Obtaining Patient-
Specific ES Cells.  In this process, the egg 
nucleus is removed (upper center) and is 
replaced by the nucleus from a patient (upper 
left).  The egg is stimulated to divide, from 
which a blastocyst is obtained (center).  ES cells 
can then be isolated from the blastocyst for 
treating the patient.  This procedure has not yet 
been successful with humans, but has been done 
in mice. 
http://www.kumc.edu/stemcell/images/scnt.jpg  
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Adult Hematopoietic Stem Cells 
 Hematopoietic stem cells (HSCs) are stem cells present in bone marrow or umbilical cord 
blood that can give rise to all blood cell types, including lymphoid and myeloid lineages. 
Hematopoietic tissue consists of cells with short and long-term regeneration capacities, including 
committed unipotent, oligopotent, and multipotent progenitors. Unipotent are cells that can 
produce only one cell type, but still are able to self-renew, which distinguishes them from non-
stem cells. Oligopotent stem cells can differentiate into a few types, and multipotent stem cells 
can produce a larger variety of a closely related family of cells.  HSCs can be found in adults’ 
bone marrow, which includes ribs, hip, sternum and other bones. They are often removed and 
collected from the hip using a needle and syringe, or from peripheral blood from individuals pre-
treated with cytokines to stimulate the release of HSCs into the bloodstream. HSCs are also 
relatively abundant in umbilical cord blood, which has recently become a popular source for 
their extraction (Viacord, 2008).  
 HSCs are widely used in bone marrow transplants (Hematopoietic Stem Cells, 2001) 
giving hope to people with various diseases such as myelodysplasia, acute leukemia, and 
congenital immune deficiencies (BMT: Success Stories: Interview with Michael Green). The 
current challenge is to reduce the rejection risk of this kind of transplant, and increase the 
number of patients who can safely access this treatment.  
 
Adult Neuronal Stem Cells 
 It used to be thought that people are born only with a particular number of neuronal cells 
that would not replenish. However, now it is known that in some regions of our brain, neuronal 
cells are continuously replenished. These neurons are derived from neuronal stem cells (NSCs). 
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NSCs are adult stem cells that are capable of differentiating into different neuronal family cell 
types, like neurons and glia. This property gives hope for scientists to use NSCs for treating 
neurodegenerative diseases such as Parkinson’s or Alzheimer’s diseases (Björklund and 
Lindvall, 2001).  
 However, it is incredibly difficult to isolate NSCs. They are located in the walls of brain 
ventricles –  cavaties filled with cerebrospinal fluid, but only one out of 300 cells of this region 
are NSCs. Over the last few years, it was shown that changing the cellular environment might be 
able to cause a transdifferentiation of NSCs into non-neural tissue; under certain experimental 
conditions NSCs can generate a large number of non-neuronal cells, such as muscle cells 
(Cassidy and Frisén, 2001).  
 
Adult Cardiac Stem Cells 
 For several decades scientists debated whether a human heart can repair itself by 
producing new tissue after serious injuries, such as heart attack. But nowadays, researchers are 
sure that the human heart contains stem cells that enable the heart to generate new cells when it 
is damaged. Cells that give rise to cardiomyocytes (heart muscle cells) located on the surface of 
the heart (epicardium) may be able to regenerate heart (Andrews, 2008).  Scientists have isolated 
these cardiac stem cells from rats and showed that after these cells are injected into a rat’s 
damaged heart, the tissue was completely renewed (Touchette, 2003). A similar procedure was 
performed in a human body. After being accidentally shot, one person suffered a massive heart 
attack. Cardiac stem cells were isolated from his own heart and placed in the artery that carried 
blood to the front of his heart producing a successful regeneration of heart muscle (Philikovski, 
2003).  
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Adult Epithelial Stem Cells 
 It has been known for some time that hair follicles within the cutaneous epithelium 
harbor a population of slowly dividing “label-retaining” cells of exceptional proliferative 
capacity.  These proliferative cells reside within a ‘bulge’ of the outer root sheath (Figure-3), and 
are capable of participating in morphogenesis of hair follicle and the adjacent interfollicular 
epidermis. According to an article published in Nature Biotechnology in 2004, some of the 
studies have indicated that cells from the bulge are bipotent, and can migrate downward in the 
hair follicle and also outward to resurface the epidermis in response to wounding.  
 
 
 
Figure-3:  Diagram of the Location of Epidermal Stem 
Cells.  The epidermal stem cells are located in a bulge midway 
down the shaft (shown in blue), and are thought to regenerate 
epidermis following wounds, or to regenerate additional 
follicles.  
http://www.nature.com/nbt/journal/v22/n4/pdf/nbt0404-393.pdf  
 
 
 
 
 Another type of epithelial stem cell is able to regenerate mouse mammary glands.  In an 
article published in Nature in 2006, experiments performed both in vitro and in vivo show that 
mammary cell differentiation originates in uncommitted stem cells with self- renewal potential 
(Khavari, 2004). 
 “Here we report the use of multi-parameter cell sorting and limiting 
dilution transplant analysis to demonstrate the purification of a rare subset 
of adult mouse mammary cells that are able individually to regenerate an 
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entire mammary gland within 6 weeks in vivo while simultaneously 
executing up to ten symmetrical self-renewal divisions. These mammary 
stem cells are phenotypically distinct from and give rise to mammary 
epithelial progenitor cells that produce adherent colonies in vitro. The 
mammary stem cells are also a rapidly cycling population in the normal 
adult, and have molecular features indicative of a basal position in the 
mammary epithelium.” (Khavari, 2004) 
 
 
Mesenchymal Stem Cells 
 Mesenchymal stem cells (MSCs) (Figure-4) are another well characterized type of adult 
stem cell. These cells are found in bone marrow (in addition to HSCs) and can differentiate in 
vitro and in vivo into a variety of tissues, including osteoblasts, chondrocytes, myocytes, 
adipocytes, and pancreatic β-islet cells. Culturing marrow stromal cells in the presence of 
ascorbic acid, or other osteogenic stimuli, can promote their differentiation into osteoblasts. 
Whereas, culturing them in the presence of transforming growth factor-beta (TGFβ) can induce 
chondrogenic markers. Unlike other types of adult stem cells, MSCs can easily be obtained in 
quantities sufficient for clinical applications. The techniques for their isolation and amplification 
in culture are well known and they can be maintained and propagated in culture for long periods 
of time.  
 
 
Figure-4:  Immunohistochemical Staining of Mesenchymal Stem Cells. 
http://www.hyclone.com/advancestem/somatic_cellular_engineering.htm 
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Adult Intestinal Stem Cells 
 Adult intestinal stem cells are one of the best studied of all the adult stem cells. Since the 
intestinal lining wears out every two to five days, intestinal stem cells are required to produce 
new cells. Intestinal stem cells give rise to various cell types inside the small intestine, including 
cells to absorb foods, cells that produce mucus, cells that excrete substances used in cell-cell 
communication, and cells involved in protection against different diseases, including bacteria 
and viruses. These cells are thought to self-renew throughout adult life due to the presence of 
both multipotent stem cells and unipotent progenitor cells.  
 
 
 
 
Figure-5:  Photograph of Epithelial Stem Cells in the Colon.   
http://www.rvc.ac.uk/Education/Undergraduate/BScVetPathology/R
esearchProjects200304.cfm  
 
 
 
 
 Recently it was discovered that there are several types of adult intestinal stem cells 
present in the intestine at the same time.  The June 8th online issue of  Nature Genetics reported 
that Mario Capecchi, the University of Utah’s Nobel Laureate, and geneticist Eugenio Sangiorgi, 
noticed that a gene named Bmi1, used to mark adult stem cells, showed the presence of adult 
stem cells only in the upper third of the intestines of mice. That means that at least one or two 
types of adult stem cells must be present in the intestine to maintain the other two thirds of the 
intestine. This discovery also raises the possibility of using these cells to replace damaged 
intestine (More Than One Kind ….. 2008).  
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iPS cells 
 Induced pluripotent stem cells (iPSs) are adult cells induced to a de-differentiated state by 
transfection of specific genes.  The first iPS cells were discovered by Shinya Yamanaka and his 
team at Kyoto University, Japan in 2006. The experiments involved transfection of mouse adult 
fibroblast cells with four genes using retroviruses.  The transfected genes included Oct3/4, Sox2, 
c-Myc, and Klf4.  The new cells took on an ES-like state, which could provide an alternative 
source for ES cells rather than destroying embryos.  However, it is not clear whether such cells 
will have the same full potentials as ES cells.  The iPS cells differed from ES cells in their DNA 
methylation pattern and when injected into developing embryos, the iPS lines were not able to 
produce chimeras (Cyranoski, 2008).  
 Nevertheless, in June 2007, the same group published a breakthrough article along with 
other independent research teams from Harvard, MIT, and UCLA showing that transfection of 
mice fibroblasts can be successful and the production of chimeras is possible. Compared to the 
first studies, the scientists used a different marker (Nanog, instead of Fbx 15).  DNA methylation 
differences were eliminated, and viable chimeras were produced, showing that Nanog is a major 
determinant of pluripotency. The only issue occurring during these studies was the fact that one 
of four genes turned out to be carcinogenic, causing cancer in about 20% of mice. In later reports 
Yamanaka managed to create chimeras without using c-Myc, even though it took a much longer 
time and the process, in general, was not efficient.   
 In November 2007, two different articles published in Science and Cell claimed that 
human iPS cells were created.  Two different research groups – James Thomson and colleagues 
at the University of Wisconsin, Madison and Shinya Yamanaka with his group at Kyoto 
University, Japan, successfully transformed human fibroblasts to pluripotent stem cells using the 
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same technique that was earlier applied in experiments with mice. In Yamanaka’s studies the 
same four genes tested earlier with a retroviral system were used; whereas Thomson used Oct4, 
Sox2, Nanong, Lin28 and a different lentiviral system in his studies (Yu, 2008).  
 
 
 
Figure-6:  Photograph of Human Induced Pluripotent 
Stem Cells.  Shown are human fibroblast skin cells induced 
by transfection to become ES-like.  Such cells may 
eventually serve as an alternative source for ES-like cells 
without destroying an embryo.   
http://www.foxnews.com/story/0,2933,312294,00.html  
 
 
 The biggest problem according to “Stem Cell Alchemy Refined”, published by Brandon 
Keim on September 25,2008  with iPS cells is the fact that the viruses used to reprogram cells 
tended to fuse with the cell DNA, which leaded to various mutations and cancer. 
 Nowadays, scientists are working on developing new methods of transferring the de-
differentiation inducing genes and discovering new alternative sources of stem cells. A new 
source of pluripotent stem cells was discovered in Januray 2007, when a group of scientists from 
Wake Forest School of Medicine extracted amniotic cells and grew them in the laboratory. The 
resulting cells turned out to be pluripotent stem cells very similar to ES cells, but not exactly the 
same. For example, ES cells injected into the muscle can form teratomas, while amniotic derived 
ES like cells do not.  According to Dr Paolo De Coppi who worked on this research, he believes 
that “ the range of applications for these amniotic ES-like cells may be more narrow than for ES 
cells”. Moreover, there are lots of limitations, that can prevent usage of this type of cells, such as 
difficulties with collecting the amniotic fluid, and even ethical and moral issues (New Stem 
Cell…2007).  
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 An article saying that another new source of ES-like cells was recently published in the 
October 8, 2008 online edition of Nature.  A group from the Center for Regenerative Biology 
and Medicine in Tuebingen, Germany, harvested stable ES-like stem cells from spermatogonial 
(sperm producing) cells taken from the routine tissue biopsies of the testes of 22 adult male 
humans.  The ES-like cells could be differentiated into all three germ layers by using the same 
techniques used to differentiate ES cells.  According to the lead author Thomas Skutella, “the 
advantage of these cells in comparison to embryonic stem cells is that there are no ethical 
problems and they are natural”.  The Professor also claims that cells in women’s eggs might be 
equivalent to the male testicular stem cells, but George Daley a stem cell scientist at Children’s 
Hospital in Boston and the Harvard Stem Cell Institute said this is unlikely, leaving women 
without this easy ES cell method (Paddock, 2008).  
 
Existing ES Stem Cell Lines 
 Federal money currently can not be used for deriving new ES lines, as will be discussed 
in more detail in Chapter-4, but ES lines derived prior to this deadline are available for federally 
funded research, as are ES lines generated with private or state funding.  For example, two 
scientists from Harvard Universirty used private funding to establish seventeen freely available 
stem cell lines. One hundred fifty new stem cell lines were recently generated by Reproductive 
Genetics Institute and scientists from UCSF have established ES cell lines using human feeder 
cells instead of the usual mouse feeder cells. Today, both UK and the US are moving forward in 
establishing private stem cell banks to help researchers all over the world (Charmany, 2004).  
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ES Cells from Excess IVF Embryos  
 According to the “Stem Cell Primer”, published in 2004 by Chamany K,“(I)n 2003 the 
RAND Institute for Civil Justice and Health determined that there were 396,526 frozen embryos 
stored for in vitro fertilization (IVF) clinics in the U.S.”  Of these, about 11,000 embryos are 
destined for scientific research, 2.2 % are planned for discard, 2.3 % are to be donated to other 
recipients, 4.5 % of the donors have lost contact with the clinics and the rest of the embryos are 
destined for future implantation. Because some embryos were inadequately preserved, only 275 
of 11,000 destined for research are viable.  However, even though they are available for research, 
they cannot be used for therapeutic purposes for a number of reasons. There is a high possibility 
of getting genetic problems, since most of the people who get involved with IVF carry fertility-
related genetic abnormalities, and genomic imprinting patterns could be irregular. Using 
extranumerary IVF embryos causes a lot of debate between scientists and ethicists because those 
embryos would not be used for reproductive purposes, as will be discussed in Chapter-3 
(Charmany, 2004). 
 
ES Cells from Embryos Created Specifically for Research via IVF 
 Most of the stem cell institutes and IVF clinics nowadays are asking women to donate 
their unused oocytes for stem cell research. This involves making women undergo the IVF 
procedure so that ES cells can be derived by removing the inner cell mass.  But as mentioned 
above this method of obtaining ES cells causes a lot of ethical issues (Charmany, 2004). 
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ES Cells from Artificial Parthenogenesis 
 Parthenogenesis is a form of asexual reproduction, in which an egg develops into a new 
individual without being fertilized. This process is common for some animals, mainly ants, 
aphids and bees.  In mammals, the process is not natural but can be induced by chemicals.  In 
order to mimic the sperm’s arrival, scientists use starvation, electrical current, or chemicals to 
stimulate the unfertilized egg to begin dividing. Soon after this, the unfertilized egg becomes 
diploid by duplicating its genetic content but does not become haploid thereafter. Studies in 
monkeys and mice have shown that pluripotent ES cells can be derived from blastocysts formed 
through artificial parthenogenesis (Cibelli et al., 2002). Since these embryos are not capable of 
completing their development, the ethical concerns about potential life can be minimized, 
although egg donation must still occur (Charmany, 2004).  In humans, the first six-cell embryos 
created by artificial embryogenesis were generated by Jose Cibelli and his group at Advanced 
Cell Technology. These embryos did not grow to the blastocyst stage from which ES cell lines 
could be established, so this technique in humans requires further development. 
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CHAPTER 2:  STEM CELL RESEARCH AND APPLICATIONS 
 
 The purpose of this chapter is to discuss examples of stem cells and their applications in 
many biomedical and scientific fields, especially for the possibility of finding treatments for 
some very complicated diseases. Much knowledge about stem cells and their potential arise from 
animal experiments that allow us to proceed into human clinical trials with appropriate 
regulations. With the recent success in isolating human adult stem cells from tissues other than 
bone marrow (a stem cell source which has already been in use for decades), it is now possible to 
consider human clinical trials for diabetes, Parkinson’s disease, or spinal cord injury, that can not 
be treated by bone marrow transplantation. Additionally, current advanced blood stem cell 
treatments applied beyond the traditional uses for chemotherapy and radiation have been 
expanded to include other non-blood uses.  The purpose of this chapter is also to help sort hype 
from documented medical studies.  
 
 
 
HEMATOPOIETIC STEM CELL APPLICATIONS 
HSCs and Cancer Chemotherapy 
 Hematopoietic stem cells (HSCs) are the most characterized of all the stem cell types.  
HSCs have been in use for over 30 years to treat specific types of blood diseases, so this type of 
stem cell will be the first discussed in this chapter.  HSCs have long been used to treat patients 
who have undergone chemotherapy and radiation treatments for cancer that destroy rapidly 
dividing cancer cells in the patient’s body, but which also destroy the patient’s own rapidly 
dividing HSCs and weaken the patient’s immune system making him or her extremely 
susceptible to many opportunistic infectious diseases (“Hematopoietic Stem Cells”, 2005). HSCs 
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transplants help replace the blood cells destroyed by chemotherapy.  HSCs are collected either 
from the patient himself, or from a histocompatible donor, and are traditionally obtained from the 
bone marrow, or from the peripheral blood following stimulation of their release from the bone 
marrow using hormones (such as G-CSF).  The HSCs are stored until the patient is clear from 
drugs in chemotherapy, and then the patient will receive a transfusion of his or her stored HSCs.  
When the patient receives his own HSCs back, there is no chance of immune mismatch or graft-
versus-host disease (GVHD). However, cancer cells are sometimes accidentally collected with 
their HSCs, which can be reintroduced back in the patient along with the HSCs, so current 
research focuses on purifying HSCs from other cells prior to infusion, and on using umbilical 
cord blood which has broader compatibility. In the case of an allogeneic transplant, where HSCs 
are obtained from a matched donor (generally a family member, sibling, preferably an identical 
twin) patients can be placed at high risk to acquire GVHD and possible rejection of HSCs if not 
treated with additional medications (“Hematopoietic Stem Cells”, 2005). 
 
HSC Treatment of Leukemia and Lymphoma 
 Leukemia and lymphoma are specific cases of blood cancers where HSC treatments were 
first clinically applied.  These cancers result from the uncontrolled production of white blood 
cells, and include acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), 
chronic myeloblastic leukemia (CML), Hodgkin's disease, multiple myeloma, and non-
Hodgkin’s lymphoma (Thomas and Clift, 1999; “Hematopoietic Stem Cells”, 2005). 
Some clinical studies have been performed over the past decade to compare the effect of 
various types of HSCs for treating these particular types of blood-cancers. The study of 
Utsunomiya et al (2001) reviews the outcome of a clinical trial of allogeneic stem cell 
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transplantation (allo-SCT) on 10 Japanese patients who had adult T cell leukemia/lymphoma 
(ATL). Allo-SCT is only an option for patients with a human leukocyte antigen (HLA)-
genetically-identical sibling. Some of the symptoms of ATL are lymph node swelling, enlarged 
liver and spleen, skin lesions, and irregular peripheral blood lymphocytes (i.e. convoluted or 
lobulated nuclei). Human T-lymphotropic virus type I (HTLV-I) is one of the documented causes 
of ATL. During the clinical period of ATL, patients usually suffer severe infectious diseases 
since their immune system is highly compromised. Conventional chemotherapy treatment is 
poorly effective for ATL due to a high rate of drug resistance for the cancer cells. Other 
alternative treatments have not yet been established (Utsunomiya et al, 2001). 
 In this study, the 10 patients included seven males and three females.  Nine of them 
received allo-SCT from their HLA-identical siblings, while one patient received HLA from an 
unrelated donor. Eight patients had acute ATL, one a lymphoma, and one chronic ATL.  
Compared to the general medial survival rate for patients with acute or lymphoma-type ATL 
during conventional chemotherapy or allogeneic bone marrow transplantation (allo-BMT), the 
medial survival rate for patients in this trial was significantly greater, 17.5 months (range 3.7 to 
34.4 months) versus 3 to 9 months with conventional treatments. In addition, the relapse rate was 
relatively lower. Only two patients relapsed during clinical ATL, and four patients died because 
of complications (GVHD, pneumonitis, gastrointestinal bleeding, or renal insufficiency). Two of 
the four died because their donors actually were positive HTLV-I carriers, which strongly 
affected the overall outcome of the treatment efficiency. The outcome of this clinical study 
suggests that allo-SCT can become a more effective treatment if post-transplant complications 
can be limited (Utsunomiya et al, 2001). 
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 In another study, Korbling and colleagues (1995) performed a human clinical study on 
nine patients with refractory leukemia or lymphoma using peripheral blood HSCs for allogeneic 
transplantation (allo-PBSCT). This study focused specifically on the issues of unstable 
engraftment durability, and the risk of GVHD compared to allo-BMT. All the donors were 
patients’ HLA-genetically-identical siblings. The drug filgrastim was subcutaneously 
administered to each donor to stimulate the mobilization of HSCs into peripheral blood. The 
authors found that the neutrophil recovery rate after allo-PBSCT was not significantly different 
from that the control group of allo-BMT, however there was a higher engraftment durability, 
higher rate of survival, and lower risk for acute GVHD.  Only one patient died of parainfluenza 
pneumonia while the other nine remained in complete remission.  The acute GVHD occurred 
mostly on the skin and was manageable with medication and close follow-up. This favorable 
outcome indicates that the use of peripheral HSCs in allo-PBSCT provides great potential for 
controlling post-transplant complications (Korbling et al, 1995).  
 By studying the efficiency of each type of treatment, scientists are learning to improve 
the outcome of the treatment and to minimize possible risks. The above studies have shown a 
possibility of reducing the risk of GVHD by using HSCs from peripheral blood that offers more 
potential than from HSCs from traditional bone marrow. GVHD has been a major concern for 
patients who receive HSCs, even from matched donors.  Further knowledge of different sources 
of HSCs will help to overcome this challenge to improve the survival rate for these patients.  
 
HSCs and Umbilical Cord Therapy 
 A more recent application for HSCs involves their isolation from umbilical cord blood.  
Figure-1 illustrates how HSCs from the umbilical cord can be stored and later used for a patient’s 
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autologous stem cell transplantation (auto-SCT) for leukemia treatment. Using the patient’s own 
purified filtered stem cells can help reduce the risk of transplant rejection, limit complications, 
and shorten the patient’s treatment period.  Due to the success of cord HSC treatments, by 2006 
more than 20 public banks to collect, store, and distribute donated umbilical cord blood or 
hematopoietic progenitor cells (HPCs) existed in the United State. Recognizing the success of 
this technique, a national umbilical cord stem cell bank has been recommended by the U.S 
Congress to establish a coordinated system with well-structured regulations and oversight. In 
states with fewer restrictions on stem cell research, such as California and Massachusetts, there 
has already been an increase in the number of private stem cell banks for collection, storage, and 
distribution services. New England Cord Blood Bank and ViaCord are examples of large cord 
companies located in Boston. Countries such as Canada, Australia, New Zealand, and the U.K. 
also have both national and private banks (Open Directory Project, 2008).  
 
 
 
 
 
 
 
 
 
Figure-1: Umbilical Cord Blood HSCs.  This diagram describes the isolation of 
umbilical cord blood from a donated cord (upper left), its amplification (upper center), 
and subsequent perfusion into a patient following chemotherapy or radiation therapy 
(upper right).  Cord HSCs represent an excellent alternative source for these cells 
compared to bone marrow or peripheral blood.  (Verfaillie, 2002) 
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NEURAL STEM CELL APPLICATIONS 
 The recent discovery of the regenerative capability of adult neural stem cells (NSCs) 
gives hope to possibly repairing damage from neurodegenerative diseases such as Parkinson’s 
disease, Alzheimer’s disease, stroke, or brain and spinal cord injuries. 
 
Treatment of Parkinson’s Disease Using NSCs 
 Parkinson’s disease (PD) is a neurodegenerative disease that results in a loss of 
dopaminergic (DA) neurons in the substantia nigra area of the brain. The neurotransmitter 
dopamine plays an important role in regulating the nerves that control body movement. 
Therefore, movement difficulties are the main signs of PD. Once administered into the body, 
Levodopa will be converted into dopamine. So far, it is the most effective drug to help treat 
symptoms of PD.  However, the drug initially helps most patients, but the side effects of the drug 
increase over time and the drug becomes less effective (Levodopa Information, 2008). A more 
promising approach to treat PD is to use cell therapy to replace DA neurons to reverse the cell 
damage caused by this devastating disease. The concept is to implant cells into the brain that can 
replace the lost dopamine-releasing neurons. Cells tested in animal models for PD include 
embryonic stem (ES) cells, adult neural stem cells (NSCs), and fetal tissue transplants from the 
ventral mesencephalon (VM). In humans, only a very limited number of VM tissue transplants 
have been tested so far (Morizane et al., 2008). In recent years, other cells have also been tested 
in animal models, including NSCs derived from fibroblasts, and HSCs derived from umbilical 
cord and bone marrow (Figure 2). 
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Figure-2: Strategies for the Cell Therapy of Parkinson’s Disease. This figure shows various possible transplant 
donor sources for PD including, from left to right, ventral mesencephalon tissue grafts, neural stem cells derived 
from fetal brain or adult brain, embryonic stem cells derived from blastocysts or induced fibroblast cells, and 
hematopoietic stem cells. The primary goal is to obtain high enough numbers of DA-neuron progenitors that are 
functional in the host brain and have no risk of tumor formation (Morizane et al., 2008). 
 
 With respect to animal models for PD, fetal tissue graft treatments have been investigated 
for decades now.  In the early 1970s, it was found that fetal tissue transplanted directly from the 
developing nigro-striatal pathways of embryonic mice into the anterior chamber of an adult rat’s 
eye continues to mature into fully developed dopamine neurons. In the early 1980s, researchers 
extended these observations to investigate transplantation of fetal tissue into the damaged areas 
of the brains of rat and monkey PD models. Researchers were able to demonstrate that a 
functional recovery depended on the implanted neurons growing and making functional 
connections at the appropriate brain locations (Dunnett et al., 2001). 
 Human trials using tissue transplants have not yet shown significant improvements in PD 
symptoms.  The validity of early 1990’s trials has been questioned, including lack of a control 
group, a small sample size, and differences in chosen criteria (Björklund et al, 2003).   However, 
in 2001, a double-blind, fully controlled,  large sample size, three year, NIH-funded clinical trial 
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using VM tissue from aborted fetuses was performed which showed improvement in patients 
below 60 years of age (Freed et al., 2001). The trial included severe PD patients who underwent 
sham surgery with no drill penetration through the dura mater but penetrated the frontal bone. All 
patients received standard PD drug levodopa prior to the study and had shown some responses to 
it.  No immunosuppressant was needed in the trial. The authors could not conclude that their cell 
therapy technique was more effective than the control in the older group of severe PD patients 
over 60 years old, did show some improvement in the group below 60 years old (Freed et al, 
2001).  Patients were asked to record their Unified Parkinson’s Disease Rating Scale (UPDRS) 
Scores as one of the measurement methods for their improvement; the higher the score, the 
worse the Parkinsonism symptoms (range from 0-176). UPDRS scores improved 34% in the 
younger group compared to 16% in the total (young plus old) transplant group. Men showed 
better improvement than women. There was no difference in adverse events recorded from the 
tested group versus control (Freed et al, 2001).  The survival of DA neurons and their growth 
was measured by the uptake of 18F-Fluorodopa (a dopamine analog) via positron-emission 
tomographic (PET) scans. Figure-3 shows an increase in the uptake of 18F-Fluorodopa (red) in 
the bilateral regions of the putamen in the brain twelve months after the surgery (Figure-3, upper 
right). Before the surgery, uptake occurred only in the caudate region of the PD patient. The 
sham surgery group (Figure-3, lower) showed no change of uptake. 
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Figure-3:  The Survival of Transplanted Fetal Tissue Grafts in Human 
Parkinson’s Patients.  Fluorodopa PET Scans indicating change in 18F-
Fluorodopa Uptake in the Brains of Patients with Parkinson’s Disease after 
transplantation (Freed et al, 2001). 
 
 The survival and growth of neurons were observed for another three years after the 
transplantation, and the authors concluded that the transplantation was successful for the younger 
group and the treated PD patient’s had restored DA neurons.  The authors indicated that less 
severe PD patients might benefit more from the cell transplantation since all of the patients in 
their study were severe. They also suggested transplanting more cells into the putamen with less 
injection sites to minimize trauma. Imaging studies might also help monitor which individual 
patient responds positively to the therapy (Björklund et al, 2003).  
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 Takagi (2005) showed that recent treatments with L-dihydroxyphenylalanine (L-DOPA) 
combined with fetal DA neuron transplantation have not been very effective due a high-risk of 
post-transplant complications (including involuntary movements or dyskinesia), a limited 
number of donor cells, and a lack of stability of the donated fetal brain tissues. Other alternative 
cell sources should be investigated further to reduce these complications for a better treatment 
outcome.  
 With respect to ES cells, most of the PD success stories are for animal models of the 
disease (Bjorklund et al, 2002; Kim et al, 2000; Studer et al, 1998; and Wernig et al, 2008). 
While the use of ES cell lines has been limited, HSCs from stored cord blood or from a patient’s 
own bone marrow might offer a promising treatment for PD as well as other neuronal diseases 
(Verfaillie, 2002; and Nikolic et al, 2008). 
 
Treatment of Alzheimer’s Disease Using NSCs 
 Another related neuronal disease that is increasingly common and is known to act by 
killing brain cells is Alzheimer's disease (AD).  AD is the most common progressive dementia 
and is pathologically characterized by deposition of amyloid-β peptide (Aβ) in the brain 
parenchyma (Nikolic et al, 2008).  Scientists still do not fully understand the causes of this 
destructive deposition pathway, and this limited understanding is a major barrier to the discovery 
of truly effective and potent therapies that might cure or mitigate this troublesome 
neurodegenerative disorder (Goldstein, 2005). Recently, there has been a great interest in using 
human embryonic stem cells in the fight against AD due to their regenerative capacity, however 
to date little animal and no human clinical trials have been performed for stem cells and AD.   
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 A study done this year by Nikolic et al (2008) shows that human umbilical cord blood 
cells (HUCBCs) possess a unique immunomodulatory potential. HUCBCs have been shown to 
“produce a number of neurotrophic factors and cytokines that modulate inflammatory responses, 
including nerve growth factor, colony stimulating factor-1, thrombopoietin, and IL-11”.  It has 
been shown that the modulation of immune responses by diverse strategies including Aβ 
immunization, nonsteroidal anti-inflammatory drugs, and manipulation of microglial activation 
states can reduce Alzheimer’s disease (AD)-like pathology and cognitive deficits in AD 
transgenic mouse models. These cells are hypothesized to possibly alter AD-like pathology after 
infusion into a transgenic mouse model of AD. The authors reported a reduction in Aβ levels or 
amyloid plaques after the injection of HUCBCs, indicating that these cells can help reduce AD-
like pathology through suppression of deleterious inflammatory responses involving the CD40 
pathway (which involved in the Aβ-induced proinflammatory microglial activation) (Nikolic et 
al, 2008). The results also show an improvement in the life spans of the AD mice. As more 
research is completed, further knowledge of this new stem cell approach can be refined. 
 
OTHER THERAPEUTIC APPLICATIONS 
Mesenchymal Stem Cells 
 In addition to containing HSCs, bone marrow also contains mesenchymal stem cells 
(MSCs). MSCs were first identified in the pioneering studies of Friedenstein and Petrakova in 
1966 to isolate bone-forming progenitor cells from rat marrow. MSCs were found to be located 
within the stromal compartment of bone marrow, and have the capacity to differentiate into cells 
 33
of connective tissue lineages, including bone, fat, cartilage and muscle (Figure-4). The 
therapeutic use of marrow-derived MSCs has been reported recently in cardiovascular repair, 
spinal cord injury, and bone and cartilage repair in animal models (Barry and Murphy, 2004). 
Local delivered MSCs can generate de novo myocardium, indicating that MSC therapy might be 
useful in treating human coronary artery disease (Barry and Murphy, 2004).    
 
Figure-4: The Differentiation of MSCs Into Various Tissues. Undifferentiated MSCs grown in monolayer culture 
(A) and after differentiation along the osteogenic (B), adipogenic (C) and chondrogenic pathways (D) and (E). Cell 
differentiation is these cultures was observed following staining with von Kossa (B), Nile red O (C), Safranin O (D) 
and by immunostaining with an antibody specific for type II collagen (E) (Barry and Murphy, 2004). 
 
 In 1999, a study done by Gussoni and his colleagues showed that murine MSCs can be 
induced to express dystrophin in association with the muscle fiber sarcolemma when injected 
into the quadriceps muscle of mdx mice. This is considered as a potential direction for therapy to 
treat the devastating condition of muscular dystrophy. In another study, after β-galactosidase-
expressing human MSCs were injected into the left ventricle of CB17 SCID/beige adult mice, 
the labeled cells were found to disperse throughout the myocardium and expressed desmin, 
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cardiac-specific troponin T, α-actinin and phospholamban, all indicative of differentiation of the 
engrafted cells to a mature myocardial phenotype (Toma et al., 2002). MSCs have also been 
shown by Ortiz et al. (2003) to engraft at high levels in lung tissue following exposure to 
bleomycin, and to offer protection against bleomycin-induced lung injury, including 
inflammation and collagen deposition. 
 Currently, most clinical data has supported the therapeutic efficiency of transplanted 
MSC therapy but additional information is necessary to understand the mechanisms of 
engraftment, homing, and in vivo differentiation of these cells. Further studies should explore 
other methods for better tissue-specific delivery of cells to improve the long-term effect of the 
therapy (Barry and Murphy, 2004). 
Adult Cardiac Stem Cells (CSCs) 
 Adult cardiac stem cells (CSCs) (Figure-5) have been shown in animal models to 
differentiate into multiple cell types in the heart, including cardiac muscle cells, indicating that 
the adult heart still has the ability to differentiate into functional cells and tissues (Segers and 
Lee, 2008). This alternative cell-based therapy does not have any of the ethical concerns of ES 
cells, and may help treat cardiac related diseases (Segers and Lee, 2008).   
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Figure-5:  Heart Muscle Repair Using Cardiac Stem Cells or HSCs.  This figure shows the repair of 
heart muscle in a rat model for heart disease using either adult cardiac stem cells (upper left) or adult bone 
marrow HSCs (upper right)  (“Can Stem Cells Repair a Damaged Heart”, 2005). 
 
 In 2005, Laugwitz and colleagues at the University of California discovered a rare 
cardiac progenitor cell called isl1+ cells in the atrium of the human newborn’s heart. These cells 
can fully differentiate into mature heart muscle while in fetal growth stage. This extraordinary 
finding brings hope for potential therapeutic treatments of various newborn cardiac diseases, and 
to replace damaged heart muscle cells in people suffering heart attacks. 
 Much progress in treating heart damage using HSCs in many rodent studies has led 
researchers to conduct human trials. Small trials have been implemented in which patients were 
injected with their own HSCs to avoid transplant rejection. However, the findings from those 
studies were mixed (Schächinger et al., 2006).  Other human studies still have not found much 
improvement compared to rodent studies, with no statistically significant difference among the 
treated group and the non-treated group (Lunde et al, 2006).   
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 In conclusion, the experience learned from these cardiac studies suggests that more 
studies need to be performed while controlling factors that can affect the outcomes, such as the 
stage of the disease, and the number of transplanted cells delivered at targeted sites. It was 
observed that most patients from the above human trials were at the advanced stage with very 
low chance of recovery. It seems that while both adult and ES cells still hold a great interest for 
treatment of these dangerous illnesses, prevention through lifestyle risk reduction should always 
first be taken into account to avoid suffering from heart disease. 
 
Treatment of Diabetes Using Stem Cells 
 Diabetes mellitus is a disease in which pancreatic beta cells become destroyed preventing 
the production of insulin. Diabetes is currently the seventh leading cause of death in the United 
States, with nearly 200,000 deaths reported each year. The American Diabetes Association 
estimates that nearly 16 million people, or 5.9 percent of the United States population, currently 
have diabetes (“Stem Cells and Diabetes”, 2005). Animal research has indicated stem cells may 
also be used to treat this disease. Additionally, the limited amount of cadaver-donated islet tissue 
available for transplant has focused on using renewable stem cells for treatment. A substantial 
body of research in animal models for diabetes indicates that either ES cells or iES cells induced 
from fibroblast cells might be successful (Roche et al, 2003; Lumelsky et al, 2001; and Itkin-
Ansari et al, 2003).   
 Despite the current controversial issues surrounding ES cells, their self-renewal and 
differentiation ability can be applied to create insulin-secreting structures similar to pancreatic 
islets (Soria et al., 2001a).  Soria et al (2001b) studied the ability of transplanted mouse ES cells 
to restore beta-like insulin-secreting cells and normal blood glucose levels in diabetic mice 
 37
(Figures 6 and 7). These immortal ES cells offer a wide range of advantages compared to 
conventional pancreatic transplantation, as they can be produced in large quantities, at relatively 
low cost, and with relatively low risk for infection or complications. The insulin producing cells 
can also easily be purified in vitro by selecting cell lineage specific surface markers (in this case, 
for insulin-containing cells) along with drug resistant genes (Soria et al, 2001a,b). 
 
Figure-6:  Differentiation of Mouse ES Cells Into Insulin Producing Cells.  Panel A: 
Undifferentiated ES cells (light color) growing on a feeder layer of mitotically inactivated mouse 
fibroblasts (dark color). Panel B: Production of insulin-secreting cells (brown) after undergoing 3 
wks of selection and maturation (Soria et al, 2001b). 
 
 
 
Figure-7:  Analysis of Insulin Producing Cells 4 Months Post-Transplant.  Panel A: X-Gal 
staining showing the presence of cells transfected with drug resistence genes. Panel B: 
Visualization of insulin producing cells 4 months post-transplant using  insulin antibody (Soria et 
al, 2001b). 
 
 
Chapter-2 Conclusion 
  
 Scientific studies over the last 30 years have shown that stem cell therapy has the 
potential to cure some devastating diseases, however more research needed before cell-based 
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therapy can broadly be applied in clinical practice. This chapter has discussed the potential of 
stem cells through numerous studies over the last few decades. Stem cell treatments are still in 
their premature stage that involves complex mechanisms we do not yet fully understand. The 
process may require many more years to practice in clinics.  With respect to future research, we 
can be certain that with less restrictive legal regulations, more federal support, open-minded 
public awareness, and worldwide collaboration, many current obstacles both technical and social 
can be overcome.  
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Chapter-3:  Stem Cell Ethics 
 
Perhaps more than any other new technology in recent memory, the topic of stem cells is 
as controversial as topics get, focusing on the very meaning of life itself and when it begins.  
Although the vast majority of people are in favor of working with adult stem cells (ASCs) 
because no embryo is destroyed, work with embryonic stem (ES) cells is highly controversial 
based on the way those cells are obtained.  The purpose of this chapter is to discuss the ethics of 
stem cell research, as one way of documenting the effects of this controversial technology on 
society.  
 
Ethical Overview 
Although stem cells have been researched in animals since the mid 1960’s, the public’s 
awareness of stem cells greatly increased in 1998 with the discovery of a method for isolating 
and growing human ES cells (Thompson et al., 1998), thus the topic has received much recent 
debate.   The ethics of the destruction of an embyro has been discussed extensively since the 
early 1970’s when human IVF embryos began widespread use.   
 There are few serious ethical concerns with extracting adult stem cells from bone 
marrow, skin, or umbilical cords, so long as donor permission is obtained.  Although the most 
potentially useful stem cells are still considered to be ES cells derived from early human 
embryos because they are pleuripotent, during the process of extraction of ES cells from the 
inner cell mass of a blastocyst the embryo is usually killed.   
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Opinions on when personhood is actually achieved can be divided into two major groups: 
pro-lifers and pro-choicers (Robinson, 2002). Most pro-lifers believe that human personhood 
starts at the conception, and the pre-embryo receives a soul, whereas pro-choicers think that 
human personhood starts after gestation. Pro-lifers suppose that the extraction of stem cells from 
the embryo is a form of experimentation on human bodies or a murder.  
Ethicists and lawyers that oppose ES cell research believe that an embryo is a human 
being that has a soul. Extracting stem cells from the embryo is a murder. In "Human Stem Cells. 
Ethical Concerns: extracting stem cells” stem cell research was compared to manufacturing of 
lampshades made of human skin during the Nazi holocaust (Robinson, 2002). Even though the 
lampshades might have been very useful, the person was killed during the production. Moreover, 
extraction of the initial stem cells from the very first embryo ever used for these purposes was a 
violation of NIH policy, and the following usage of the cells is not only an immoral act, but also 
a violation of government regulations (Robinson, 2002). Robert George, a professor of moral and 
political philosophy at Princeton says, that “embryos possess the epigenetic primordia for 
internally directed growth and maturation as distinct, self-integrating, human organisms. Because 
of this, he regards an embryo as being already—and not merely potentially—a living member of 
the human species” (Robinson, 2002).  
Lawyers and medical ethicists that are in favor of using ES cells argue that these cells are 
not capable of growing into a complete person. “They cannot be considered a form of human life 
since they can grow only into a certain organ but not a complete human being” (Robinson, 
2002). While ES cells have an enormous promise to save millions of lives and to treat diseases, 
most of the spare embryos in fertility clinics will die anyway following donor consent to end the 
IVF process, operator error, or equipment malfunction. Linda Bevington, Director of Research 
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for the Center for Bioethics and Human Dignity stated: “A lot of proponents of ES cell research 
note that these embryos are extras, and they'll never be implanted, and they're doomed/destined 
for destruction anyway, so we might as well just take their ES cells and create some therapies 
and some good (Robinson, 2002). However, it is possible to adopt those embryos, termed 'rescue 
surrogacy,' and so those embryos aren't necessarily destined for destruction. They can be 
implanted, and a healthy baby can be born" (Robinson, 2002).  
Various religious communities have interpreted key stem cell issues in view of their own 
beliefs, but some large religions have never come to consensus within their own religion. Key 
topics include whether the 5-6 day old blastocyst that is destroyed to obtain ES cells has the 
same moral status as an individual.  Which embryos if any should be used for ES research?  Are 
excess embryos created at IVF clinics acceptable for use with parental consent?  Should we 
allow egg donors to get paid? Should we allow the embryos to become genetically engineered if 
it saves lives?  Should we allow the patenting of ES cell lines by private companies?  Who 
should have access to these expensive treatments?  These key questions will be discussed in this 
chapter. 
 
Oocyte Donors 
In February 2005, Woo Suk Hwang's team (Figure-1) at Seoul National University 
published their work, where they claimed that they had derived eleven patient–specific ES cell 
lines (Hwang et al., 2005).  This process involves the use of somatic cell nuclear transfer (SCNT) 
in which the patient’s skin cell nucleus is microinjected into an enucleated egg, and the embryo 
is grown to the blastocyst stage where ES cells are extracted that are genetically identical to the 
patient.  SCNT previously worked in mice, but not in humans.  In their initial experiments, 
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Figure-1:  Photo of Dr. Hwang Woo-suk and his 
stem cell team at Seoul National University. 
http://msnbcmedia4.msn.com/j/msnbc/Components/
Photos/060109/060109_suk_vmed_7p.widec.jpg  
 
Hwang and his colleagues used cells from a single 
female donor to try to create ES cell clones. An oocyte 
nucleus was extracted and injected back into an 
enucleated egg from the same woman.  Since both the 
nuclei and the egg belonged to one and the same 
person, the scientists were not able to “rule out the 
possibility that the ES line was derived from the 
parthenote”.  But in his later experiments, Hwang 
claimed that he had overcome this concern by placing 
nuclear material from one volunteer into the egg of 
another volunteer, therefore creating an ES clone 
matched to the nuclear donor.  This was ground 
breaking, but later it was discovered that much of his data was fabricated (Charmany, 2004). 
This was just the first of many ethics issues to arise. In the subsequent investigation into his lab, 
it was determined that a high number (20) of oocytes were used, and the women donors were 
paid about $ 1,430 each.  Moreover, two of his junior lab workers donated their oocytes under 
pressure (Holden, 2005). However, Dr. Hwang in his interview in Time magazine in December 
2005, officially claimed that he was never aware of the sources of oocytes. “What we receive is 
the oocyte, not donor information” (10 Questions for Dr. Hwanf Woo Suk, 2005).   
This paper stimulated a widespread ethical debate that continues to this day, about who 
should provide the eggs, and whether the donors should be paid.  The least controversial stance 
on egg donation, which most U.S. states currently allow, is for the donation of excess in vitro 
fertilization (IVF) embryos.  These embryos were originally created for purposes of reproduction 
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not research, the donors are not paid, and the donors provide their written consent.  Since the 
advent of human IVF technology in the early 1970’s, excess embryos are usually destroyed once 
the couple is done having babies, so why not allow their use to try to save lives instead of being 
destroyed.  
 
Stem Cell Recipients 
When human ES cells are derived, to test their plasticity, it is necessary to inject the cells 
into animal or human tissue to see how the cells adapt and behave in natural environment. The 
usage of these two types of recipients brings up serious ethical questions.  When animals are 
injected with human ES cells, sometimes a chimera forms that is a combination of human and 
animal tissues.  This process makes most people feel uncomfortable, but some nations still 
permit this kind of experimentation due to the large amount of useful information obtained.  
The second type of recipient is people suffering from different diseases. Even though it might 
seem to be less controversial, human rights organizations still strictly control the use of these 
patients (Charmany, 2004). 
 
 Universal Access to Stem Cell Therapies 
Many scientists and ethicists have shown concern that potentially expensive stem cell 
therapies might not be available to under-represented minorities, since it is usually thought that 
they have less financial capital.  But as is typical of any new therapy, it may begin expensive, but 
eventually costs come down and this issue may diminish over time.  In the Stem Cell Primer 
(Charmany, 2004) they suggest two different ways of overcoming this problem.  The first is to 
use a “maximum coverage approach” to establish universal stem cell banks that would provide 
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ES cells genetically engineered to be immunologically compatible with any ethnic group.  The 
alternative way is to move forward using an “ethnic representation strategy”, which would 
provide ES cells with HLA types for every ethnic group (Charmany, 2004).  
Another approach that will maximize access to stem cell therapies, is to use more widely 
available adult stem cells, such as umbilical cord blood hematopoietic stem cells (HSCs), since 
banks storing this type of blood can serve the largest number of individuals.  And since this 
blood is obtained from a newborn baby who has an immature immune system, cord blood HSCs 
are far less likely to stimulate GVHD (graft versus host disease) than bone marrow HSCs.  
Moreover, cord HSCs may show high plasticity, and are able to differentiate into other tisues 
besides blood.  In August 2005 a group of scientists published a report showing their capability 
to expand cord blood cells into those with ES cell properties. This team managed to establish a 
protocol that offers a large supply of cells that do not require human/animal chimeras, or the 
destruction of an embryo (Charmany, 2004).  
 
Genetic Modification and Stem Cell Research 
Genetically modifying stem cells might be used to improve symptoms related to genetic 
diseases via therapeutic transplants expressing the normal version of the mutated gene, or for 
developing embryos with inactive genes to help understand the functions and roles of specific 
proteins (Charmany, 2004).  However the genetic manipulation of embryos has been a highly 
controversial topic since it was first performed by Mengele during World War II.   In perhaps the 
most infamous uses of genetically modification of human cells, at Auschwitz/Birkenau 
concentration camps, doctor Joseph Mengele performed horrific experiments on people with a 
goal of creating the best “Aryan” race through genetic modifications (Weber, 1985).  
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In a more positive use of genetic modification, HSCs have been modified to include 
therapeutic genes to treat patients using gene therapy.  Gene therapy experiments have had great 
success in animal models and have had some minor success in humans.  This technique is 
viewed by many researchers as life saving medicine (Charmany, 2004).  Gene therapy is not yet 
a perfect procedure, some tests using viruses as vectors caused a mutation in the patient’s B cells, 
and in others it caused anaphylactic shock.  One of the most important factors to be taken into 
account is to ensure no modifications occur to the patient’s germ cells, which would permanently 
distribute the modification to all cells of the patient’s offspring.  One way to avoid this 
happening was suggested by Mario Capecchi at the University of Utah, who proposed using 
artificial chromosomes to allow the scientists to insert genetic information and turn it on or off 
whenever desired (Charmany, 2004). Reminiscent of Mengele, the idea of creating a “perfect” 
human being is appealing to some.  
Another ethical concern of human genetic modification can be shown in the “Muscle 
Boy” example. A gene mutation that affected production of a growth regulator caused extreme 
muscle development and strength. Soon thereafter, to obtain similar muscular effects, a few high 
school athletic coaches contacted the scientists and asked for help (Charmany, 2004). 
 
Religious Influences on Stem Cell Research  
The subject of stem cell research is widely discussed by representatives of all major 
religions. Countless debates have been published and stated in several past decades, however the 
consensus between the religions on the topic of stem cell research (especially ES cell research) 
have never been reached.  In order to determine whether ES cells should be used, it is necessary 
to determine the ontological status of the human embryo.  
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Judaism 
Representatives of Judaism believe that human bodies belong to God, and we have them 
on loan throughout our life.  Since God is the owner of our bodies, he can impose certain 
conditions on their use.  One of these requirements is that people have to search for ways to 
preserve human life and health. Hence, we are obligated to find and develop new cures for 
human diseases.  This kind of tradition approves both natural and artificial ways of overcoming 
illnesses (Dorff, 2002). 
 According to Jewish biblical and Talmudic laws, the status of human as a person is 
acquired with time, progressively, not at fertilization (Cousins, 2004). This means that according 
to the Talmud, during the first forty days of gestation the human fetus is “as if it were simply 
water”, implying that human status is not given to a fetus until it reaches forty first day (Dorff, 
2002).  Because ES cells are derived from 5-6 day old embryos with the same status as water, 
Judaism supports the use of ES cells and goes beyond that to encourage it. 
Indirectly supporting the destruction of IVF embryos, Rabbi Yosef Sholom Eliyashuv, 
one of the most influential poseks in Israel today, has permitted preimplantation diagnosis and 
the destruction of the affected zygote in cases with Fragile-X (sex-linked disease), Tay Sachs 
disease, and neurofibromatosis (Eisenberg, 2001). Pre-implantation diagnosis likely will be 
accepted in the near future by most Jewish legal experts when used to prevent serious diseases. If 
the pre-embryo is allowed to be destroyed after this sort of diagnosis, it certainly can be used for 
ES research and other life-saving work (Eisenberg, 2001).  Rabbi David Feinstein also supports 
using spare IVF embryos (Eisenberg, 2001). 
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Buddhism and Hinduism 
Even though some Hindu believers place the beginning of personhood between three and 
five months, the majority of traditional Hindu believers think that conception is the beginning of 
soul’s rebirth from a previous life (Cousins, 2004).  According to Buddhist teaching, it is almost 
impossible to assume that a particular phenomenon is unnatural. Nowadays it might be difficult 
for Buddhism to deal with some bioethical problems, since Buddhist ethics “does not utilize the 
concept of being natural” (Promta, 2004).  In general, Buddhism supports the attempts to gain a 
new knowledge as long as the acquisition is controlled by wisdom, and wisdom is a process of 
practical long-term learning. Regarding ES cell research, there are many sources in the Buddhist 
texts saying that killing an embryo is not any different from killing an adult, meaning that the use 
of ES cells even for curing some diseases is the same as using the life of an adult in order to save 
another adult’s life. However, donating somebody’s life for the benefit of another is considered 
to be goodness, which is proved by several examples described in various Buddhist literatures 
(Promta, 2004).  
 
Islam 
In his interview given on April 2007, Muzammil Siddiqi, President of the Fiqh Council of 
North America states that embryonic stem cell research is supported by Islamic traditions. One 
of the points that he brought up to prove that ES research is not an amoral act is the fact that 
embryos being used for ES research do not yet have personhood.  According to the beliefs in the 
Quran, life starts after forty days from fertilization, well after blastcyst formation. A clear 
difference between the early stages of the pregnancy (the first forty days) and its later stages was 
established by Muslim jurists: it is said that if a woman with an early stage pregnancy is  
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attacked, and the baby was aborted during the act, the criminal’s punishment would be less than 
that of the criminal who did that act during later stages of pregnancy.  And if the child was killed 
after birth, the criminal would be punished for infanticide (Muzammil, 2008).  
The other factor that Muzammil Saddiqi pointed out is the idea that using excess embryos 
from IVF clinics should be supported and financed by the government, since this has fewer 
ethical concerns than alternative embryo donations.  Muslims believe that there should be a clear 
distinction between “having something in the test tube or dish versus having something in the 
body of a human being”. If the embryo is not present in its natural environment (the womb), it 
cannot survive and become a complete human being, hence the excess IVF embryos can be used 
for ES research (Stem Cell Research in Shari'ah Perspective 2007).  
“However, it is important that we establish strict rules against the misuse of embryos. 
Research on embryos has the potential for misuse, for instance in regards to the donors of 
these cells, and we should anticipate what these misuses might be, and establish 
safeguards against them. (For example, doctors might have an infertility client 
inappropriately undergo extra cycles of ovulation just so they can obtain more embryos, 
or they might pay women to produce embryos, or the embryos might be obtained without 
the consent of the donors). In making rules, the authorities should also clarify that there is 
a difference between the use of “spare” embryos from IVF procedures which would be 
destroyed regardless, compared to the deliberate production of embryos. Each year 
thousands of embryos are wasted in fertility clinics around the world. Such embryos 
should not be wasted, they should be used for research” (Muzammil, 2008).  
 
Catholicism  
The Roman Catholic church is one of the main embryonic stem cell opponents. Catholics 
believe that a “living human embryo is, from the moment of union of the gametes, a human 
subject with a well defined identity, which from that point begins its own coordinated, 
continuous and gradual development, such that at no later stage can it be considered as a simple 
mass of cells” (deDios, 2000).  Moreover, they believe that it is not morally licit to use cloned 
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human embryos for therapeutic purposes.  The church maintains that every single embryo (no 
matter how it was produced) should be given a chance to develop into a mature human being 
(Cousins, 2004).  With respect to Catholicism, it should also be pointed out that as is the case 
with very large religions, not all believers agree on their stem cell stance.  It is clear the Pope as 
church leader is against destroying embryos, but several prominent Bishops have taken stances 
against the Pope on this issue when lives are at stake. 
Several days after Yamanaka and his team announced that they had created induced 
pluripotent stem (iPS) cells, President George Bush claimed that nowadays the research can be 
conducted “within ethical boundaries”. iPS cells are adult skin fibroblast cells induced to de-
differentiate into ES-like cells by inserting 2-4 key genes that function in de-differentiation. 
However, a week later Yamanaka told Nature magazine that the discovery of creating pluripotent 
stem cells from adult stem cells can actually bring even more ethical concerns. For example, 
producing eggs from the male iPS cells might allow a gay couple to produce offspring. 
Moreover, scientists working with iPS cells right now can be tempted to create a live, cloned 
human. Yamanaka’s concerns about ethical issues convinced Japan’s government to create a 
regulation forbidding “the implantation of embryos made with iPS cells into human or animal 
wombs, the production of an individual in any other way from  iPS cells, the introduction of iPS 
cells into an embryo or fetus, and the production of germ cells from iPS cells” (Cyranoski, 
2008). 
 
Protestantism 
Different Christian denominations have completely different views on the embryonic 
stem cell research. For instance, the American Presbyterian church accepts the idea of using 
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embryos for therapeutical and research purposes, while the Southern Baptist convention is 
strongly against it (Cousins, 2004), and Protestants believe that an early embryo should be 
respected as a complete human being with his own soul. According to Karl Barth, one of the 
twentieth-century theologians, “No community, whether family, village or state, is really strong 
if it will not carry its weak, and even its very weakest members” (Holland et al., 2001 pp. 142-
143). 
 
 Naturalistic Worldview 
 Most people with naturalistic views value the life of an embryo, and do not support any 
artificial embryo technnology (Cousins, 2004).  Naturalists are “for the life of any embryo over 
any present malady-ridden human”. This is one of the reasons they do not support stem cell 
research (Calamaio, 2007). 
 The second argument naturalists have against ES cell use is it represents a sophisticated 
form of cannibalism. Although most people don’t view cannibalism as eating an embryo, people 
with a naturalistic view believe that an embryo’s life was ended when its stem cells were 
consumed by the member of the same species. And from the embryo’s standpoint, “whether 
injected into the receiving body, or chewed up by the recipient - this is a distinction without a 
difference” (Calamaio, 2007).  A species growing and consuming its own preborn cannot be 
supported by naturalists.  
 However, other naturalists do support IVF reproductive technology, growing embryos 
(not stem cells) for healthy adulthood.  Using the rubberized womb, which they believe can be 
created using current technologies, people could avoid issues with alcohol damaged babies, 
tobacco damaged babies, drug damaged babies, or junk food damaged babies. Moreover, this 
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kind of method might be beneficial for women who don’t want to deal with pregnancy and 
giving birth (Calamaio, 2007).  
 
Chapter-3 Conclusion 
With respect to stem cell ethics, most of the attention has been paid to ES cell research, 
mainly because obtaining ES cells requires destruction of an embryo.  None of the major world 
religions is against working with adult stem cells, especially when human lives can be saved.  
For many people, ES research conflicts with their cultural and religious views, since it involves 
destruction of potential life. For others (especially Judiasm and Islam who argue that life begins 
well after the blastocyst stage), the potential of ES research to provide cures and treatments for 
debilitating diseases is more important.  As for the author of this IQP chapter, the possibility of 
finding a cure for serious illnesses such as diabetes, Alzheimer’s disease, Parkinson’s disease, 
heart disorders and many others, overrides most of the ethical and religious concerns, so long as 
strong oversight is used to ensure egg donors are not paid money and that excess IVF embryos, 
normally slated for destruction, are used as the primary source of embryos to derive ES cell lines.  
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CHAPTER 4:  STEM CELL LEGALITIES 
 
Research on human embryonic stem cells (hESCs) offers much promise for 
understanding and treating disease that benefits hundreds of thousands of people, however as 
discussed in Chapter-3, because their derivation destroys an embryo these cells have strong 
ethical concerns. As is the case for most controversial technologies, laws have been enacted to 
govern ES cell uses and derivations, so the purpose of this chapter is to discuss some of these 
laws both in the US and abroad.    
With proper regulation and new ways to obtain these potential saving-life cells, hopefully 
the objections of hESC research can somehow be resolved in favor of the beneficial use of these 
cells. The U.S. policies on stem cell research seem to change every time a new President is 
elected. Despite numerous achievements in this promising field, and despite all the efforts to 
explore new sources of stem cells, the lack of federal support and funding under the current Bush 
2001 legislation has left this country behind in novel discovery and practical applications. 
Countries such as the U.K., India, China, Australia, Canada, Sweden and some other European 
nations have caught up and even surpassed the U.S for the last decade on the ES topic. The new 
presidential election is approaching in just a couple of weeks as we are finishing this IQP report, 
and the future of stem cell research in this country might change dramatically depending on who 
takes office, especially given that the two candidates hold very different points of view on ES 
research. This chapter is designed to discuss the current stand of U.S. legislature at both federal 
and individual state levels, as well as drawing a broad picture of the worldwide view on stem cell 
research. 
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Human Embryonic Stem Cell Research Laws in the U.S. 
Federal laws 
President Clinton was the first president to endorse stem cell research. Under his legacy, 
The National Institute of Health (NIH) was authorized to allocate funds to experiments that 
would create new embryos specifically for research. It had opened many doors to researchers 
with sufficient grants for creating specific cell lines using embryos in from the IVF process 
(Dunn, 2005). 
However, when President Bush took office in 2001, his restrictive policy reduced a great 
number of ES cell lines for research.  Below is a statement from President Bush on August 9, 
2001 allowing federal funding only on ES cell lines established before that date: 
"As a result of private research, more than 60 genetically diverse stem cell lines already exist" I 
have concluded that we should allow federal funds to be used for research on these existing stem 
cell lines " where the life and death decision has already been made", This allows us to explore 
the promise and potential of stem cell research" without crossing a fundamental moral line by 
providing taxpayer funding that would sanction or encourage further destruction of human 
embryos that have at least the potential for life."     (Bush, 2001) 
 Under this policy, the NIH’s Human Embryo Research Panel (HERP) was required to 
withdraw or review grant research that had previously been approved under the Clinton 
Administration. HERP was also ordered to reexamine the derivation of those existing cell lines, 
mainly developed from excess embryos created reproductive purposes by in vitro fertilization 
(IVF). Under this policy, the U.S. government currently provides no federal funding for any 
therapeutic cloning research for the purpose of creating hESC (Dunn, 2005).    
 One key assumption of this policy was that the existing number of ES cell lines would be 
sufficient to evaluate this new technology without having to destroy any new embryos, however 
the number of ES cells lines has dwindled over the years.  In 2001, Bush’s advisors estimated 
there were 64 ES cell lines (Table I). 
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Name  Number of cell lines  
BresaGen, Inc., Athens, Georgia  4 
CyThera, Inc., San Diego, California  9 
Karolinska Institute, Stockholm, Sweden  5  
Monash University, Melbourne, Australia 6 
National Center for Biological Sciences, Bangalore, India  3  
Reliance Life Sciences, Mumbai, India  7 
Technion-Israel Institute of Technology, Haifa, Israel  4 
University of California, San Francisco, California 2 
Göteborg University, Göteborg, Sweden  19 
Wisconsin Alumni Research Foundation, Madison, Wisconsin  5 
 Total 64 
 
Table 1:  Number of ES Cell Lines as of August 9, 2001. There were 64 cell lines in 
existence at ten laboratories around the world (AAAS, 2007). 
 
 However, of the 9 ES cell lines listed at Göteborg University in Sweden claimed by NIH, 
it was found by The New York Times that “12 were still in early stages, 4 were still being 
characterized, and only 3 were characterized enough for study ” (AAAS, 2007). 
In 2002, a year after President Bush announced his stem cell policy, the NIH stem cell 
registry listed 78 eligible cell lines that met the President's criteria for publicly funded research, 
but only 16 of those 78 were available for federally funded use. In 2006, according to Guhr et al 
(2006), there were only 20 out of 71 different hESC lines listed in the NIH Stem Cell Registry 
available to researchers. With this limited availability of stem cell sources, it is not surprising the 
U.S. is falling behind in the international competition for this advanced technology. 
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Presidential Candidates’ Agenda for Stem Cell Research 
 
The upcoming November 2008 Presidential election will decide whether the doors for 
advanced biomedical research that existed under the Clinton legacy will be reopened. Senator 
Obama is a strong supporter for future therapeutic stem cell approach with promise for curing 
many serious diseases. Senator McCain’s point of view is not much different from the current 
Bush administration.  Below is the web release from Senator McCain’s campaign to address the 
moral concerns of stem cell research (underscores provided by IQP author):  
“Stem cell research offers tremendous hope for those suffering from a variety of deadly diseases - 
hope for both cures and life-extending treatments. However, the compassion to relieve suffering 
and to cure deadly disease cannot erode moral and ethical principles.  For this reason, John 
McCain opposes the intentional creation of human embryos for research purposes. To that end, 
Senator McCain voted to ban the practice of "fetal farming," making it a federal crime for 
researchers to use cells or fetal tissue from an embryo created for research purposes. Furthermore, 
he voted to ban attempts to use or obtain human cells gestated in animals. Finally, John McCain 
strongly opposes human cloning and voted to ban the practice, and any related experimentation, 
under federal law.  As President, John McCain will strongly support funding for promising 
research programs, including amniotic fluid and adult stem cell research and other types of 
scientific study that do not involve the use of human embryos.  Where federal funds are used for 
stem cell research, Senator McCain believes clear lines should be drawn that reflect a refusal to 
sacrifice moral values and ethical principles for the sake of scientific progress, and that any such 
research should be subject to strict federal guidelines.”    (McCain-Palin Campaign, 2008) 
 
On the other hand, Senator Obama has optimistically expressed his support for this 
potential biomedical breakthrough as in his statement of support for stem cell research sent to 
President Bush in 2006. Below is his plan for future stem cell research posted on his campaign 
website:  
“Advance Stem Cell Research: Human embryonic stem cells have great potential for treating a 
wide variety of diseases and health conditions and for providing new insights into human 
development and disease. An Obama Administration will reverse the Bush Administration’s ban 
on federal funding for embryonic stem cell research on cell lines created after August 9, 2001 by 
executive order and will allow all scientists to participate in this important new field, in accord 
with the rigorous ethical guidelines proposed by the National Research Council.” 
                                     (Obama-Biden Campaign, 2008) 
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State Laws 
Although there is little support for ES cell research with federal funds, especially 
blastocyst preimplantation research, some states have become pioneers to use state funding and 
contributions from private sector for their research progress. These progressive states include 
New Jersey, California, Massachusetts, Wisconsin, New York, Connecticut, Maryland, and 
Illinois. On the hand, several states hold very strong voices opposing such research programs. 
These conservative states have criminalized stem cells research, including North Dakota, South 
Dakota, Arkansas, Louisiana, Indiana and Michigan (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1- Current US States That Individually Support and Oppose ES Cell 
Research (Wadman, 2008).  
 
New Jersey  
Three years after Bush enacted his restrictive policies on stem cell research, in January 
2004, Governor James McGreevey signed a law that made NJ the first state to use state funding 
for stem-cell research and somatic-cell nuclear transfer (SCNT) with an initial package of $10 
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million. Another $270 million was added into the state fund in 2006 with the approval of new 
Governor Jon Corzine. However, a 2007 bill did not pass for a new funding of $450 million by 
NJ voters because of complications in the research criteria to use of human embryonic stem cell 
as well as a deficit for the state budget for that year (Wadman, 2008). 
 
California 
In November 2004, California became the second state to support ES stem cell research 
by passing the Proposition 71 research initiative program of $3 billion over the period of 10 
years with $300 million in funding annually (CIRM website). Following this historic proposition, 
the California Institute for Regenerative Medicine ("The Institute" or "CIRM") was established 
in the following year to monitor and distribute the grant money. Although there were some legal 
challenges to overcome from the beginning, CIRM has become more organized with its 29 
members in the Independent Citizens’ Oversight Committee (ICOC). The ICOC members are 
from areas of patient advocates, research institutes, and the business and general community of 
the state to provide better grant management with various sub-committees. Grant money of $45 
million has been distributed to more than 72 applicants from 2 to 4 years since 2006. Other 
funding has also been awarded to graduate students, post doctorate fellows, and other major 
research institutions to support teaching and training projects on stem cell research (Trounson, 
2008).  CIRM also encourages positive competition and collaboration among institutes within 
the state, as well as with the other eight states that also support stem cell programs. They have 
increased efforts to connect major for-profit private sector companies around the country and 
international collaboration for joint-projects and funding to ensure major impact and success for 
therapeutic disease treatments (Trounson, 2008). 
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Massachusetts 
 In May 2007, Governor Deval Patrick proposed $1 billion in state funding for biomedical 
research over a 10 year period, in which about $500 million of this grant would be used to 
establish a research centre that would house the nation's largest embryonic stem-cell bank. The 
plan is to create the Massachusetts Stem Cell Bank for storage of new ES cell lines, which are 
also made available to all research sectors, both public and private. Major local hospitals with 
academic institutes have been discussed to participate in this collaboration, including Boston 
University, Brigham & Women’s Hospital, Children’s Hospital, Harvard University, 
Massachusetts General Hospital, the Massachusetts Institute of Technology, Partners HealthCare 
and the University of Massachusetts.  Other projects also include bridging the NIH funding gap, 
Massachusetts Life Science Fellowship Grants, and funding Innovation Centers (Governor 
Patrick Public Release, 2008).  
In another statement on November 2007, Governor Patrick showed his strong support for 
the investment in this life science field: 
"We want Massachusetts to provide the global platform for bringing innovations from the 
drawing board to the market, from inspiration to commercialization, and from ideas to cures.  
Our rate of innovation in recent years has been triple that of the national average and I have no 
intention of letting it slip."  (Governor Patrick, Whitehead Institute, 11/10/07) 
 
The new funding will also offer significant impact on the growth of numerous ongoing projects 
around the state. In September 2008, the President and CEO of the Massachusetts Life Sciences 
Center, Susan Windham-Bannister discussed with the WPI community her expectations for the 
growth and support of research and investment in life sciences in Worcester (WPI News Release, 
2008). In recent years, Worcester has experienced a significant increase in the growth of many 
private life sciences companies, along with the expansion of a research center at the University 
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of Massachusetts Medical School.  Worcester is also the home of WPI Life Sciences and 
Bioengineering Center at Gateway Park, where appropriate funding will open doors to many 
great achievements in many fields (WPI News Release, 2008). 
It is recognized that federal funding from the NIH plays a major role in providing the 
fundamental resources for many basic biomedical initiatives. With limited access to NIH to fund 
novel hESC discoveries, it is necessary to try different approaches to obtain appropriate funding. 
Besides state and private funding for hESC experiments, each state should also consider 
investing in less controversial adult stem cell research as an alternative approach. This year, in 
September, an award of $900,000 was granted to a research group at WPI to explore a novel way 
of transforming adult skin cells into pluripotent-like cells. The possible application of this 
research can be used to treat tissue injury, growing new organs, and offers a potential treatment 
for degenerative diseases like diabetes and Parkinson’s (WPI News Release, 2008). 
After Massachusetts, Wisconsin and New York are the next two states with a large 
amount of state funding for stem cell research, with the total amount of $750 million and $600 
million, respectively, in 2007 (Figure 1). 
 
International Stem Cell Laws 
Despite numerous achievements in this hopeful field, and despite all the efforts to explore 
new sources of stem cells, the lack of federal support and funding under the Bush 2001 
legislation has left this country behind in hESC research. Countries such as the U.K., India, 
China, Australia, Canada, Sweden and some other European nations have caught up and even 
surpassed the U.S in terms of hESC research technology and facilities.  Figure-2 shows a global 
map of which countries are permissive or conservative on ES cell research.  
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Figure 2:  Global Map Indicating Permissive, Flexible, and Conservative Countries 
on ES Cell Research.  Countries colored in dark brown have a permissive policy on 
human embryonic stem cell research.  Light brown denotes flexible countries, and yellow 
denotes conservative countries.  All countries have banned human reproductive cloning 
(Hoffman, 2007).  
 
 
 
In Figure-2, countries colored dark brown (permissive category) accept the production of 
human embryos for research purposes through in vitro fertilization and/or nuclear transfer 
(cloning) (Walters, 2007). These countries include Australia, Belgium, China, India, Israel, 
Japan, Singapore, South Korea, Sweden, and the United Kingdom. 
Countries colored light brown (flexible category) permit the derivation of new human 
embryonic stem cell lines but only by using the remaining embryos from infertility clinics 
(Walters, 2007). These countries include Brazil, Canada, France, Iran, South Africa, Spain, The 
Netherlands, Taiwan, and some others. 
The remaining countries colored yellow either exhibit restrictive policies or have not 
established a stem cell policy. Those countries that do not permit experiments with ES cells 
include Austria, Ireland, Norway, and Poland. Those with less restrictive policy that do permit 
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research with existing human embryonic stem cell lines but not the derivation of new stem cell 
lines through the destruction of human embryos include Germany, Italy, and the United States 
(Walters, 2007). 
Table-2 shows the population of the countries colored brown in Figure 2 that have 
permissive stem cell policies.  These countries represent about 3.5 billion people or more than 
half of the world’s population. 
 
 
 
Australia   20.3 M 
Belgium   10.4 M 
Brazil   188 M 
Canada   33.1 M 
China   1,314 M 
Czech Republic   10.2 M 
Denmark   5.4 M 
Estonia   1.3 M 
Finland   5.2 M 
France   62.8 M 
Greece   10.7 M 
Hong Kong   6.9 M 
Hungary   10 M 
Iceland   .3 M 
India   1,045 M 
Iran   69 M 
Israel   6.4 M 
Japan   127 M 
Latvia   2.3 M 
The Netherlands   16.5 M 
New Zealand   4.1 M 
Portugal   10.6 M 
Russia   146 M 
Singapore   4.5 M 
Slovenia   2.0 M 
South Africa   44 M 
South Korea   40.4 M 
Spain   40.4 M 
Sweden   9 M 
Switzerland   7.5 M 
Taiwan   23 M 
Thailand   65 M 
Turkey*   70 M 
United Kingdom   60.6 M 
 
Table 2:  The Total Population of the 
Permissive Countries Colored in 
Brown in Figure-2.  The permissive 
countries represent about 3.5 billion 
people, more than half the world's 
population. Population: M = million 
(Hoffman, 2007). 
 Chapter-4 Conclusion 
The pursuit and production of knowledge through advanced scientific research has 
transformed our lives in many ways. Although clinical applications using hESC therapy 
treatments have currently seen limited use in humans, the extensive experimental research on 
animals should be expanded to further our understanding of human diseases.   The potential 
health benefits of stem cell technology will require a large and sustained investment in research 
from both the U.S federal government and individual states. California has successfully 
demonstrated an excellent model for such programs, with its extensive efforts to collaborate with 
various research institutes not only within the US but also in other countries.  Massachusetts and 
other states’ on-going progress have also proven that proper funding and less restrictive 
regulation will play a major role for helping provide a promising future for stem cell 
applications.  
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CONCLUSIONS 
 
 
Research on human embryonic stem cells (hESCs) offers much promise for treating a 
variety of diseases that affect society.  hESC treatments are still in their premature stages, and 
involves complex mechanisms we do not yet fully understand, thus human hESC treatments are 
only now beginning to be tested.  However human treatments with adult stem cells (ASCs) are 
far more common, especially using hematopoietic stem cells, and have already saved thousands 
of lives.  The authors of this IQP conclude that less restrictive legal regulations should be 
enacted in the U.S., allowing more federal support for hESC research.  Open-minded public 
awareness and worldwide collaboration should help eliminate many current obstacles, both 
technical and social.  Although all five major world religions support using adult stem cells, only 
two of the five support using hESCs.  However, the authors believe that the possibility of finding 
treatments for many currently incurable human illnesses overrides most of the ethical and 
religious concerns, so hESC research should be supported.  Additionally, alternatives to using 
hESCs cells, such as parthenotes and iES cells, must be explored based on their fewer ethical 
concerns.  Adult stem cells should be used whenever possible, but some diseases will eventually 
require the use of hESCs with their greater differentiation potential.   We conclude that the 
current U.S. legal restrictions on using federal funding to support hESC research should be 
eliminated to create new hESC lines to use for life saving purposes. 
 
